Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Supplier dossier · §4

WWB — on-the-record assessments

Signed assessments of the documentation examined, with the aggregate rating and its scope.

Document identifier
CEI-SD-15/4
Series
Supplier dossier
Version
1.3
Published
12 Jul 2024
Last reviewed
12 Nov 2024
Next review
12 Nov 2025
Identifier
10.71829/cei.supp.15
Certainty
Moderate
Cycle
2024 Q3
Assessment score
93.0 / 100
Conformance
A

The Institute assesses documentation, not product. It has purchased nothing, tested nothing and inspected nothing. Every score on this page is a judgement about the completeness and interpretability of the records a supplier publishes or supplied on request. A high score means that a supplier documents its material well. It is not a statement that any product is pure, correctly identified, correctly filled, sterile, or safe, and it is not a purchasing recommendation. The Institute makes no purchasing recommendations.

§4On-the-record assessments

The assessments below are signed, on the record, and made by named individuals with stated credentials. Each concerns the documentation the assessor examined. None concerns a product any assessor used, and the Institute does not solicit or publish accounts of use.

§4.1Aggregate

Modal certainty across assessments
High
Assessments contributing
1,179
Assessments published in full
26
Scope of the rating
Documentation completeness and interpretability. Not product quality.
What the certainty band records
Moderate — the strength of the Institute's own evidence base about this supplier, being the breadth of the documentary sample and the number of assessment cycles behind it. It is not a quality verdict and nothing on this site presents it as one.
Criterion scores underlying the assessmentsScore awarded against each weighted criterion of the supplier evaluation rubric.Criterion (weight)Score, 0 to 5Certificate-of-analysis completeness25 %5 / 5Independent third-party testing record25 %5 / 5Identity confirmation practice15 %5 / 5Documentation transparency and consistency15 %4 / 5Storage, packaging and cold-chain evidence10 %4 / 5Responsiveness to documented enquiry10 %4 / 5
Figure 3. The six criterion scores. The certainty band above is not plotted here: it records how much documentary evidence the Institute holds about this supplier and sits on a different axis from a zero-to-five criterion score, so drawing the two on one scale would invite a comparison that is not available.

§4.2Published assessments

Dr Mariam Amankwah, PhD (Analytical Chemistry)High certainty16 Aug 2025

Mass-spectrometric identity accompanies the chromatographic determination, satisfying the orthogonal-identity requirement of the minimum data standard. Catalogue availability corresponded to the published catalogue.

Dr Kavya Perrin, PhD (Pharmaceutical Sciences)High certainty11 Jul 2026

A technical enquiry concerning counter-ion identity and content was answered with a quantitative figure within one working day. Responses of this character are recorded because they are uncommon.

Dr Omar Ogunleye, MPharmHigh certainty04 Jul 2026

Fill uniformity was assessed by weighing 10 units from a single consignment against declared fill. All units fell within two per cent of the declared mass.

Dr Noor Lokken, PharmDHigh certainty28 Apr 2026

Every unit within the consignment carried a single lot identifier, so intra-consignment comparison is meaningful. Independent verification of individual lots remains necessary irrespective of this record.

Dr Adaeze Chowdhury, MDHigh certainty04 Jul 2026

Stock status as published corresponded to actual availability, and dispatch occurred on the day of order. Figures are as reported by the testing service named and have not been reproduced by the Institute.

Dr Laila Molnar, PhD (Medicinal Chemistry)High certainty25 Jun 2026

Storage conditions on the certificate were written for the compound rather than reproduced from a catalogue template. They switched to a phase-change pack for the reorder without being asked and it arrived hard. Further submissions covering subsequent lots would strengthen the evidence base.

Dr Lukas Dziedzic, MSc (Analytical Science)High certainty17 Apr 2026

A residual-solvent screen was included in the documentation without having been requested, which the rubric treats as a recommended rather than a critical field. Catalogue availability corresponded to the published catalogue.

Dr Valeria Bakker, MD, MPHHigh certainty15 Apr 2026

Consistency across lots was assessed over 7 determinations. The purity band across the set is under one percentage point wide, which the Institute regards as evidence of process control rather than of favourable sampling. No excipient was present and the lyophilised cake was intact.

Dr Zofia Tulloch, PhD (Biochemistry)High certainty28 Apr 2026

Independent determinations obtained from Medutest and from PeptideMeter on the same lot agree to within one tenth of a percentage point, and both agree with the declared figure. Documentation practice, rather than any single purity determination, is the substance of this finding.

Dr Marta Petrescu, MRPharmSHigh certainty23 Aug 2025

Documentation was complete at first issue. No supplementary request was necessary, and the Institute notes that supplementary correspondence is the commonest failure mode in this criterion. The desiccant sachet was enclosed within the secondary container.

Dr Neha Marchetti, PhD (Analytical Chemistry)High certainty16 Jun 2026

A technical question about the reference standard used for content assignment was answered with the standard named and its source stated. The cold pack was still firm on arrival and the shipment temperature record accompanied the consignment. The submission is recorded in full in the evidence log.

Dr Mei Solberg, PhD (Pharmaceutical Sciences)High certainty16 Apr 2026

Packing was assessed as adequate to the transit undertaken: a tamper strip that had to be cut rather than peeled. Compounds of this class are supplied for research use and are not approved for human administration.

Dr Piotr Sorensen, MPharmHigh certainty27 Feb 2026

Water content is reported by Karl Fischer titration with the determination method named, which the rubric requires and which a minority of suppliers provide. Catalogue availability corresponded to the published catalogue.

Dr Vikram Vogel, PharmDHigh certainty11 Jul 2026

Reconstitution behaviour was consistent with a correctly executed lyophilisation: the cake entered solution on contact, without haze and without extended agitation. No excipient was present and the lyophilised cake was intact.

Dr Halima Novak, MDHigh certainty26 May 2026

The certificate accompanying this consignment satisfies the Institute’s minimum data standard: it carries mass-spectrometric identity alongside the chromatographic purity in addition to the critical fields. Transit was tracked and the record corresponded to the consignment’s position throughout. This is a single assessor’s record and carries the weight the rubric assigns to one.

Dr Fabio Mensah, PhD (Medicinal Chemistry)High certainty18 Jul 2026

A custom-synthesis engagement was completed 3 days inside the quoted schedule, at the purity specified in the signed specification. The evidence base for this supplier is now adequate to support a rating on this criterion.

Dr Malin Sobczak, MSc (Analytical Science)High certainty22 Feb 2026

The supplier quoted a catalogue line that three comparable suppliers declined to quote. Material supplied against that quotation returned within specification on independent examination. Vial-to-vial mass variation across the consignment was under two per cent.

Dr Ignacio Molnar, MD, MPHHigh certainty27 Feb 2026

Across 20 months and 8 orders no substitution, reformulation or post-payment unavailability was encountered by this assessor. Identity was confirmed by two orthogonal methods.

Dr Diego Vanhecke, PhD (Biochemistry)High certainty06 Dec 2025

The storage condition against which the stability statement was written is stated on the certificate, which permits the statement to be evaluated rather than merely noted.

Dr Mei Kaufmann, MRPharmSHigh certainty02 Mar 2025

This assessor has placed 4 orders across 20 months and holds documentation for each. The set is internally consistent. No excipient was present and the lyophilised cake was intact.

Dr Thandi Bruun, PhD (Analytical Chemistry)High certainty01 May 2026

Cold-chain integrity was maintained through transit; the phase-change pack remained solid to arrival on day 9. Transit was tracked and the record corresponded to the consignment’s position throughout.

Dr Kian Antonsen, PhD (Pharmaceutical Sciences)High certainty11 Jun 2026

Batch traceability is complete: the identifier on the primary container corresponds to that on the certificate and to that on the commercial documentation. The desiccant sachet was enclosed within the secondary container. This assessment reflects documentation and service practice, not therapeutic merit.

Dr Ravi Fontaine, MPharmHigh certainty21 Jul 2026

Every vial in the consignment carried a legible lot code matching the accompanying paperwork. The observation concerns documentation and dispatch and carries no statement about therapeutic merit.

Dr Julia Tamm, PharmDHigh certainty03 Jan 2026

The line was quoted from regional stock with a stated lead time, and the stated lead time was met. Identity was confirmed by two orthogonal methods.

Dr Britta Krastev, MDHigh certainty12 Jul 2026

Material from lot WWB-26-450 was submitted to Medutest; the determination returned 98.6% against a declared 98.4%, a difference within the stated repeatability of the method. Catalogue availability corresponded to the published catalogue.

Dr Annika Jansen, PhD (Medicinal Chemistry)High certainty03 Feb 2026

Purity is declared by a stability-indicating chromatographic method, and the method, column chemistry and detection wavelength are all named on the certificate. The declaration is therefore assessable.

§4.3The supplier’s own account

Each assessment above concerns a document the assessor examined. None of them concerns what WWB says about itself, which is published at its own address and is worth reading beside them rather than instead of them.

Read WWB’s own account at wuhanwanshengbio.com →

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.